Abstract: The invention relates to novel proangiogenic compositions, to the method for preparing same, and to the uses thereof, particularly for preventing or treating any disease causing ischemic-type complications.
Type:
Grant
Filed:
March 28, 2011
Date of Patent:
December 23, 2014
Assignees:
Institut des Vaisseaux et du Sang, Universite Paris Diderot Paris—7
Abstract: Proteins having the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4, or fragments of said sequences are provided. The protein fragments are represented by the sequences of SEQ ID NO: 2q, q varying from 3 to 36, and the sequences of SEQ ID NO: 185 to SEQ ID NO: 209. Nucleotide sequences coding for said proteins are also provided.
Type:
Grant
Filed:
January 21, 2008
Date of Patent:
April 16, 2013
Assignees:
INSERM (Institut National de la Sante et de la Recherche Medicale), Centre National de la Recherche Scientifique, IVS Institut des Vaisseaux et du Sang
Inventors:
Laurence Leconte, Esma Lejmi, Isabelle Clarisse Solange Plouët, Claire Charlotte Plouët, Anne Florence Plouët
Abstract: A cell/ligand specific marking system, the system being characterized in that it comprises: (a) an endothelial precursor cell (EPC) including a cell marker selected from among the group consisting of the Eph (in particular EphB4 or EphB1), and (b) a protein material of structure L-K, which consists of a ligand (L) specific of the marker and is associated or fused with a binding protein (K), the system being capable of providing a proangiogenetic cell material of structure EPC-Eph-L-K. The invention also concerns the cell material as product capable of stimulating angiogenesis, its preparation method and its therapeutic use, in particular with respect to vascular insufficiencies.
Type:
Grant
Filed:
July 27, 2006
Date of Patent:
December 25, 2012
Assignees:
Institut des Vaisseaux et du Sang, Universite Paris 7-Denis Diderot
Inventors:
Philippe Foubert, Sophie Le Ricousse-Roussanne, Jean-Sebastien Silvestre
Abstract: A peptide fragment of the netrin-4 protein and nucleic acids coding for the peptide are described. The peptide can inhibit endothelial cell proliferation and cell migration, as well as activate the proliferation and migration of pericytes and smooth muscle cells. Pharmaceutical formulations containing the peptide and/or the nucleic acids can be used to treat a variety of tumoral and non-tumoral pathologies.
Type:
Grant
Filed:
June 29, 2011
Date of Patent:
May 1, 2012
Assignees:
Centre National de la Recherche Scientifique, IVS Institut des Vaisseaux et du Sang
Abstract: A peptide fragment of the netrin-4 protein and nucleic acids coding for the peptide are described. The peptide can inhibit endothelial cell proliferation and cell migration, as well as activate the proliferation and migration of pericytes and smooth muscle cells. Pharmaceutical formulations containing the peptide and/or the nucleic acids can be used to treat a variety of tumoral and non-tumoral pathologies.
Type:
Application
Filed:
June 29, 2011
Publication date:
November 17, 2011
Applicants:
IVS INSTITUT DES VAISSEAUX ET DU SANG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Abstract: Described is use of a netrin selected among netrin-4, mutated netrin-4, netrin-1, netrin G1 or netrin-3, or one of their fragments or a nucleotide sequence encoding one of the netrins or one of the fragments, or an anti-idiotypic antibody of one of the netrins or of one of the fragments, or of a Fab fragment of the anti-idiotypic antibodies, for preparing a medicine for preventing or treating tumoral or non-tumoral pathologies.
Type:
Grant
Filed:
November 22, 2005
Date of Patent:
August 16, 2011
Assignees:
Centre National de la Recherche Scientifique (CNRS), IVS Institut des Vaisseaux et du Sang
Abstract: The present invention relates to a protein comprising or consisting of one of the following sequences: the sequence SEQ ID NO: 2 or SEQ ID NO: 4, or a fragment of said sequence represented by one of the sequences SEQ ID NO: 2q, q varying from 3 to 36, or the sequence SEQ ID NO: 185 to SEQ ID NO: 209. It also relates to a nucleotide sequence coding for said protein.
Type:
Application
Filed:
January 21, 2008
Publication date:
September 30, 2010
Applicants:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, IVS INSTITUT DES VAISSEAUX ET DU SANG, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC
Inventors:
Jean Plouet, Isabelle Clarisse Solange Plouet, Claire Charlotte Plouet, Anne Florence Plouet, Laurence Leconte, Esma Lejmi
Abstract: This invention has as its object a protein, preferably a glycosylated protein, having a molecular weight of about 0.6 to 200 kD, containing the following sequence which is in particular N-terminal:-Ser-Pro-Glu-Leu-Thr-Phe-,preferably:-Ser-Pro-Glu-Leu-Thr-Phe-Arg-X-Y-Thr-Ile-Ser-,where X and Y, which may be identical or different, each represent Trp or Asp.It relates in particular to a glycoprotein derived from monocytes (MECIF) and having an apparent molecular weight of 64-70 kD and containing 568 amino acid residues.Application in particular to the treatment of diabetic retinopathies, neovascularisation, arteritis, venous disorders, vascular tumors and rheumatoid arthritis.
Abstract: The invention relates to the use of .kappa.-caseinoglycopeptide or CGP, in particular from cow's ewe's, goat's or human milk, for the manufacture of a composition, in particular a medicament, for the prevention and/or the treatment of thrombi.A medicament of this kind can advantageously be presented in lyophilised form intended for injection, after being dissolved in a compatible solvent, or in the form of nanoparticles enclosed in capsules.Application to the prevention and the treatment of thrombi.
Type:
Grant
Filed:
May 9, 1990
Date of Patent:
November 5, 1991
Assignees:
Centre National de la Recherche Scientifique (CNRS), Institut des Vaisseaux et du Sang (IVS)
Inventors:
Ludovic O. Drouet, Claire Bal Dit Sollier, Elisobeth M. Mazoyer, Sylviane Levy Toledano, Pierre Jolles, Ann-Taiic D. Fiat
Abstract: The peptides according to the invention are of the following general formula I:Z-Lys-Arg-Asp-X-Y (I)wherein:X is the residue of one of the 20 common aminoacids in the L-configuration,Y is hydroxyl or the C-terminal residue of one of the 20 common aminoacids in the L-configuration,Z is acetyl, hydrogen or the N-terminal residue of one of the 20 common aminoacids in the L-configuration, as the case may be N-acetylated, whereby it is understood that:when Y is the C-terminal residue of one of the 20 common aminoacids in the L-configuration, Z is acetyl or hydrogen andX can in all cases be different from Y and from Z.Application to the preparation of anti-thrombotic medicines.
Type:
Grant
Filed:
October 28, 1988
Date of Patent:
July 24, 1990
Assignees:
Institut des Vaisseaux et du Sang, Centre National de la Recherche Scientifique
Inventors:
Pierre Jolles, Anne-Marie Fiat, Claudine Soria, Levy-Toledano Sylviane, Sanghamitra Raha, Elisabeth Mazoyer, Ludovic Drouet